[
  {
    "sentence": "Among these cancer types, breast tumors exhibited the most significant differences, indicating a potentially prominent role of SLC7A3 in breast cancer (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the GEPIA database, we further observed substantially lower SLC7A3 mRNA expression in breast cancer tissues compared to normal breast tissues (Fig. 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, direct analysis of SLC7A3 expression in breast cancer and adjacent tissues using data from the UALCAN database, based on The Cancer Genome Atlas (TCGA), confirmed a significant decrease in SLC7A3 expression in breast cancer tissues (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The level of SLC7A3 was visibly lower in breast invasive ductal carcinoma tissues compared to normal breast tissues (Fig. 2D) and showed a significant reduction in 31 pairs of tumor samples compared with adjacent normal samples (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The results revealed that SLC7A3 was expressed at low level in both breast and pancreatic cancers compared to normal tissues (Fig. 2F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Among these cancer types, breast tumors exhibited the most significant differences, indicating a potentially prominent role of SLC7A3 in breast cancer (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the GEPIA database, we further observed substantially lower SLC7A3 mRNA expression in breast cancer tissues compared to normal breast tissues (Fig. 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, direct analysis of SLC7A3 expression in breast cancer and adjacent tissues using data from the UALCAN database, based on The Cancer Genome Atlas (TCGA), confirmed a significant decrease in SLC7A3 expression in breast cancer tissues (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The level of SLC7A3 was visibly lower in breast invasive ductal carcinoma tissues compared to normal breast tissues (Fig. 2D) and showed a significant reduction in 31 pairs of tumor samples compared with adjacent normal samples (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The results revealed that SLC7A3 was expressed at low level in both breast and pancreatic cancers compared to normal tissues (Fig. 2F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on breast sample types, SLC7A3 expression was lower in primary breast cancer samples compared to normal tissues (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A decrease in the expression of SLC7A3 was observed in breast cancer patients across stages 1, 2, 3, and 4, compared to normal controls (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "For breast cancer with nodal metastasis, where SLC7A3 expression was lower in patients with breast cancer classified as N0, N1, or N2, compared to N3 (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Both TP53 wild-type and TP53-mutant breast cancer patients showed a reduction in SLC7A3 expression compared with normal controls, with significantly lower SLC7A3 expression in TP53-mutant breast cancer patients (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, SLC7A3 expression was decreased in breast cancer patients of Caucasian, Asian, and African-American ethnicity, with higher SLC7A3 levels observed in Caucasian patient tumors than in their African-American and Asian counterparts (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regarding breast cancer subtypes, HER2-positive tumors displayed a generally greater reduction in SLC7A3 expression compared to TNBC tumors and luminal breast cancer tumors (Fig. 3E).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Among the major subclasses, luminal tumors exhibited higher SLC7A3 expression than TNBC-luminal androgen receptor, HER2-positive, and TNBC tumors (Fig. 3F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SLC7A3 expression in infiltrating lobular carcinoma was higher than in most other pathological types of breast cancer (Fig. 3G), and SLC7A3 expression was higher in pre-menopausal tumors than in post-menopausal tumors (Fig. 3H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel H",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel H",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel H",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Based on breast sample types, SLC7A3 expression was lower in primary breast cancer samples compared to normal tissues (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A decrease in the expression of SLC7A3 was observed in breast cancer patients across stages 1, 2, 3, and 4, compared to normal controls (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "For breast cancer with nodal metastasis, where SLC7A3 expression was lower in patients with breast cancer classified as N0, N1, or N2, compared to N3 (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Both TP53 wild-type and TP53-mutant breast cancer patients showed a reduction in SLC7A3 expression compared with normal controls, with significantly lower SLC7A3 expression in TP53-mutant breast cancer patients (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, SLC7A3 expression was decreased in breast cancer patients of Caucasian, Asian, and African-American ethnicity, with higher SLC7A3 levels observed in Caucasian patient tumors than in their African-American and Asian counterparts (Fig. 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regarding breast cancer subtypes, HER2-positive tumors displayed a generally greater reduction in SLC7A3 expression compared to TNBC tumors and luminal breast cancer tumors (Fig. 3E).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Among the major subclasses, luminal tumors exhibited higher SLC7A3 expression than TNBC-luminal androgen receptor, HER2-positive, and TNBC tumors (Fig. 3F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "SLC7A3 expression in infiltrating lobular carcinoma was higher than in most other pathological types of breast cancer (Fig. 3G), and SLC7A3 expression was higher in pre-menopausal tumors than in post-menopausal tumors (Fig. 3H).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel H",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel H",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel G",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel H",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Breast cancer patients with lower SLC7A3 expression, as determined by the median FPKM (fragments per kilobase million) value of TCGA data, exhibited a worse overall survival (OS) according to the Human Protein Atlas Kaplan-Meier analysis module (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Patients with higher expression of SLC7A3 had a better OS, according to the results of follow-up analysis (Fig. 4B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The results revealed that breast cancer patients with high SLC7A3 expression had greater overall survival (OS), relapse-free survival (RFS), disease-specific survival (DSS), and distant metastasis-free survival (DMFS) compared to patients with low SLC7A3 expression, suggesting that SLC7A3 could act as a protective factor in breast cancer (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Breast cancer patients with lower SLC7A3 expression, as determined by the median FPKM (fragments per kilobase million) value of TCGA data, exhibited a worse overall survival (OS) according to the Human Protein Atlas Kaplan-Meier analysis module (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Patients with higher expression of SLC7A3 had a better OS, according to the results of follow-up analysis (Fig. 4B and C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The results revealed that breast cancer patients with high SLC7A3 expression had greater overall survival (OS), relapse-free survival (RFS), disease-specific survival (DSS), and distant metastasis-free survival (DMFS) compared to patients with low SLC7A3 expression, suggesting that SLC7A3 could act as a protective factor in breast cancer (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These genes include SLN, LRRC43, HEMGN, HHLA1, TDRD6, CRYBA1, NTNG1, SPATA19, and other members of the SLC family (Fig. 6A).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Functional analysis further demonstrated that these genes were related to L-type cationic amino acid transmembrane transporter activity (Fig. 6B).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Subsequently, a protein-protein interaction (PPI) network diagram for SLC7A3 was generated using the online STRING database, with 10 nodes representing proteins and 17 edges representing protein-protein associations (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The nodes included ARR3, COQ7, THOC7, CDX4, ZSCAN10, SLC7A13, SLC3A2, SLC1A4, SLC1A7, and SLC16A2 (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These genes include SLN, LRRC43, HEMGN, HHLA1, TDRD6, CRYBA1, NTNG1, SPATA19, and other members of the SLC family (Fig. 6A).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Functional analysis further demonstrated that these genes were related to L-type cationic amino acid transmembrane transporter activity (Fig. 6B).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Subsequently, a protein-protein interaction (PPI) network diagram for SLC7A3 was generated using the online STRING database, with 10 nodes representing proteins and 17 edges representing protein-protein associations (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The nodes included ARR3, COQ7, THOC7, CDX4, ZSCAN10, SLC7A13, SLC3A2, SLC1A4, SLC1A7, and SLC16A2 (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  }
]